Article Information
History
- July 29, 2025.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Eric Tatara1,*,
- Louis Shekhtman2,3,*,
- Nicholson Collier1,
- Scott J. Cotler2,
- Mary Ellen Mackesy-Amiti4,
- Basmattee Boodram4,
- Harel Dahari2,#,
- Marian Major5,# and
- Jonathan Ozik1
- 1Consortium for Advanced Science and Engineering, University of Chicago, Chicago, IL; Decision and Infrastructure Sciences, Argonne National Laboratory, Argonne, IL, USA
- 2Program for Experimental and Theoretical Modeling, Division of Hepatology, Department of Medicine, Loyola University Chicago, Maywood, IL 60153, USA
- 3Department of Information Science, Bar-Ilan University, Ramat Gan, Israel
- 4Division of Community Health Sciences, School of Public Health, University of Illinois at Chicago, Chicago, IL, USA
- 5Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA
- ↵#Corresponding authors. Harel Dahari, hdahari{at}luc.edu; Marian Major, marian.major{at}fda.hhs.gov.
↵* E.T. (agent-based modeling work) and L.S. (in-host viral dynamics work) contributed equally to this work.
Posted July 29, 2025.
Modeling highlights the challenge of maintaining HCV micro-elimination among people who inject drugs
